Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma
Status:
RECRUITING
Trial end date:
2028-01-15
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled Phase III clinical trial on the efficacy and safety of MG-K10 humanized monoclonal antibody injection in adolescent and adult patients with moderate to severe asthma.